SlideShare a Scribd company logo
ANTI OBESITY DRUGS
OBESITY
• Defined as an excess of body fat.
• Surrogate marker for body fat content Body Mass Index.
• BMI= Weight (in kg)
Height (in m2)
• BMI not a direct estimate of adiposity; large muscle mass.
OBESITY
• Can also be defined as,
• 25% or greater total body fat- men
• 35% or greater- women
• Estimation of % of total body fat:
• Measurement of skin fold thickness
• Bioelectrical impedance
• Underwater weighing
BODY MASS INDEX
BODY MASS INDEX VALUES(kg/m2)
NORMAL 18.5- 24.9
OVERWEIGHT 25-29.9
CLASS I OBESITY 30-34.9
CLASS II OBESITY 35-39.9
CLASS III OBESITY (EXTREME) > 40
According to National Institute of Health:
EPIDEMIOLOGY
• Obesity “Killer lifestyle disease”
• According to WHO,
• 1.2 billion people classified overweight worldwide
• 3% of Indian population- obese
• Lancet India is just behind US and China among top 10
countries with highest number of obese.
OBESITY
• Obesity results from greater energy intake than energy
expenditure.
• 9.3 Cal 1gm fat is stored.
• Fat adipocytes SC tissue; IP cavity; liver & other tissues.
OBESITY
• Infancy; childhood hyperplastic obesity number of
adipocytes
• Adults Hypertrophic obesity size of adipocytes
• Extremely obese size and number of adipocytes contains
double amount of lipids as a lean person
Hyperplastic Hypertrophic
WHAT CAUSES OBESITY????
OBESITY AND GENETICS
• 20-25%
• How genes contribute to obesity???
• One/ more abnormality of pathway regulating feeding center
• Abnormality of energy expenditure and fat storage
PATHOPHYSIOLOGY
• Neural centers regulating appetite, feeding, behavior and
energy status: Hypothalamus; the amygdala; nucleus tractus
solitarius (NTS).
• Lateral nuclei hypothalamus feeding center
• Ventromedial nuclei satiety center
• Arcuate nucleus floor of 3rd ventricle in hypothalamus
key site.
• These centers possess high density receptors for
neurotransmitters and hormones.
COMPLICATIONS OF OBESITY
TREATMENT OF OBESITY
ANTIOBESITY DRUGS
• Orlistat- pancreatic lipase inhibitor
• Sibutramine- serotonin-norepinephrine reuptake inhibitor
• Rimonobant- cannabinoid type-1 receptor antagonist
Newer drugs approved by FDA
• Lorcaserin- June 2012
• Phentermine & Topiramate ER- July 2012
• Naltrexone & Bupropion- Sept 2014
• Liraglutide- Dec 2014
ORLISTAT
• Reversible inhibitor of lipase- inhibits absorption of dietary
fats
• Empirical formula- C29H53NO5
• Molecular weight- 495.7
• FDA approved- April 1999
ORLISTAT- MECHANISM OF ACTION
• Exerts therapeutic activity- lumen of stomach and small
intestine
• Covalent bond active serine residue site- gastric;
pancreatic lipase
• Inactivated enzyme inhibits hydrolysis of dietary fat (TG) to
absorbable free fatty acids and monoglycerides.
• Undigested TG unabsorbed caloric deficit positive
effect on weight control.
• Therapeutic dose- 120 mg TID- fat absorption inhibited by
30%
ORLISTAT- ADR
• Fatty/oily stool
• Flatus with discharge
• Fecal incontinence
• Increased defecation
• Abdominal cramps
SIBUTRAMINE
• Serotonin-norepinephrine reuptake inhibitor
• Empiric formula- C17H29Cl2NO
• Molecular weight- 334.33
• FDA approved- November 1997
SIBUTRAMINE- MOA
• Inhibits reuptake of serotonin; norepinephrine at
hypothalamic sites
• Increases levels of these substances- enhances satiety
• Reduction in waist circumference
• Decrease in plasma TG and VLDL
• Increase in HDL
• Dose- 5-15 mg/day
SIBUTRAMINE- ADR
• Dry mouth
• Constipation
• Insomnia
• Increased BP; Heart rate
RIMONABANT
• Cannabinoid type-1 receptor antagonist
• Developed for smoking cessation; facilitate weight loss
• Initially used in pts with BMI> 30kg/m2
• Frequent adverse effects most notably severe
depression risk of suicide this drug is no longer used
clinically
LORCASERIN
• Serotonin 2C receptor agonist
• Selectively activates serotonin 2C receptors in brain
promotes satiety
• Indicated as an adjunct to low calorie diet and increased
physical activity
• BMI> 27 kg/m2 associated with weight-related comorbid
condition or BMI >30kg/m2
LORCASERIN
• Dose- 10 mg twice daily
• ADR-
• Headache, dizziness, fatigue
• Nausea, dry mouth
• Constipation
• Backache
• Cough
• Hypoglycemia
QSYMIA
• Combination of Phentermine & Topiramate ER.
• Phentermine mediates release of catecholamine's in
hypothalamus reduced appetite; decreased food consumption
• Topiramate precise mechanism unknown
• Dose- start 3.75mg/23mg daily for 14 days; increase to 7.5mg/46mg
once daily.
• After 12 weeks, <3% weight loss discontinue
QSYMIA- ADR
• Paresthesia
• Dizziness
• Insomnia
• Constipation
• Dry mouth
CONTRAVE
• Naltrexone & Bupropion
• Schedule for treatment:
• Week 1 1 tab- morning
• Week 2 1 tab- morning & evening
• Week 3 2 tab- morning; 1 tab- evening
• Week 4 2 tab- morning & evening
• After 12 weeks, <5% weight loss discontinue
CONTRAVE- MOA
• Effect on 2 separate areas of brain
• Hypothalamus
• Mesolimbic dopamine circuit
• Exact neurochemical effects not known
CONTRAVE- ADR
• Nausea, vomiting
• Headache, dizziness, insomnia
• Dry mouth
• Constipation
• Has potential to cause suicidal thoughts & behaviors.
LIRAGLUTIDE
• Glucagon like peptide 1 receptor agonist.
• A physiological regulator of appetite; calorie intake
• GLP-1 receptor- present in several areas of brain regulating
appetite.
• Dose- 3mg subcutaneously
LIRAGLUTIDE- ADR
• Hypoglycemia
• Nausea, vomiting
• Constipation
• Dyspepsia
• Fatigue, Dizziness
• Pain abdomen
OTHER TRIALS
• Beloranib- May 2015, Phase II trial
BARIATRIC SURGERY
• Most effective long-term treatment for obesity
• Several approaches used- performed laproscopically
• Goal- disrupting release of ghrelin and other peptides
enhancing satiety
• Complications:
• Post-operative respiratory problems, wound infection
• Staple leaks, stomal stenosis,
• Marginal ulcers and venous thrombosis
Antiobesity drugs
Antiobesity drugs

More Related Content

What's hot

Newer anti diabetic drugs
Newer anti diabetic drugsNewer anti diabetic drugs
Newer anti diabetic drugs
Dr.Vijay Talla
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
charithwg
 
Recent advances in the treatment of diabetes mellitus
Recent advances in the treatment of diabetes mellitusRecent advances in the treatment of diabetes mellitus
Recent advances in the treatment of diabetes mellitus
chandiniyrao
 
pediatrics pharmacology
pediatrics pharmacologypediatrics pharmacology
pediatrics pharmacology
Azad Haleem
 
Drugs of obesity - Pharmacology
Drugs of obesity - PharmacologyDrugs of obesity - Pharmacology
Drugs of obesity - Pharmacology
Areej Abu Hanieh
 
Oral hypoglycemics
Oral hypoglycemicsOral hypoglycemics
Oral hypoglycemics
ankit
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetesraj kumar
 
Prokinetics 1
Prokinetics 1Prokinetics 1
Prokinetics 1
Pavana K A
 
Drugs for the treatment of irritable bowel syndrome
Drugs for the treatment of irritable bowel syndromeDrugs for the treatment of irritable bowel syndrome
Drugs for the treatment of irritable bowel syndrome
Domina Petric
 
Pharmacology - Antimycobacterials Drugs
Pharmacology - Antimycobacterials DrugsPharmacology - Antimycobacterials Drugs
Pharmacology - Antimycobacterials Drugs
Areej Abu Hanieh
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
Dr Roohana Hasan
 
Drugs used in the treatment of irritable bowel syndrome (IBS)
Drugs used in the treatment of irritable bowel syndrome (IBS)Drugs used in the treatment of irritable bowel syndrome (IBS)
Drugs used in the treatment of irritable bowel syndrome (IBS)
Keshari Sriwastawa
 
Ezetimibe
EzetimibeEzetimibe
Ezetimibe
ZheerSN
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
Basil Wilson
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
Health Forager
 
Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)
http://neigrihms.gov.in/
 
Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016
Mohamed Sedky
 
Methotrexate - A Comprehensive Drug Review in Dermatology
Methotrexate - A Comprehensive Drug Review in DermatologyMethotrexate - A Comprehensive Drug Review in Dermatology
Methotrexate - A Comprehensive Drug Review in Dermatology
Jerriton Brewin
 
Anti thyroid drugs
Anti thyroid drugsAnti thyroid drugs
Anti thyroid drugs
madhursejwal
 

What's hot (20)

Newer anti diabetic drugs
Newer anti diabetic drugsNewer anti diabetic drugs
Newer anti diabetic drugs
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
Recent advances in the treatment of diabetes mellitus
Recent advances in the treatment of diabetes mellitusRecent advances in the treatment of diabetes mellitus
Recent advances in the treatment of diabetes mellitus
 
pediatrics pharmacology
pediatrics pharmacologypediatrics pharmacology
pediatrics pharmacology
 
Drugs of obesity - Pharmacology
Drugs of obesity - PharmacologyDrugs of obesity - Pharmacology
Drugs of obesity - Pharmacology
 
Oral hypoglycemics
Oral hypoglycemicsOral hypoglycemics
Oral hypoglycemics
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetes
 
Prokinetics 1
Prokinetics 1Prokinetics 1
Prokinetics 1
 
Drugs for the treatment of irritable bowel syndrome
Drugs for the treatment of irritable bowel syndromeDrugs for the treatment of irritable bowel syndrome
Drugs for the treatment of irritable bowel syndrome
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Pharmacology - Antimycobacterials Drugs
Pharmacology - Antimycobacterials DrugsPharmacology - Antimycobacterials Drugs
Pharmacology - Antimycobacterials Drugs
 
Hypolipidemic drugs
Hypolipidemic drugsHypolipidemic drugs
Hypolipidemic drugs
 
Drugs used in the treatment of irritable bowel syndrome (IBS)
Drugs used in the treatment of irritable bowel syndrome (IBS)Drugs used in the treatment of irritable bowel syndrome (IBS)
Drugs used in the treatment of irritable bowel syndrome (IBS)
 
Ezetimibe
EzetimibeEzetimibe
Ezetimibe
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
 
Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)
 
Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016
 
Methotrexate - A Comprehensive Drug Review in Dermatology
Methotrexate - A Comprehensive Drug Review in DermatologyMethotrexate - A Comprehensive Drug Review in Dermatology
Methotrexate - A Comprehensive Drug Review in Dermatology
 
Anti thyroid drugs
Anti thyroid drugsAnti thyroid drugs
Anti thyroid drugs
 

Similar to Antiobesity drugs

Obesity
ObesityObesity
Obesity
Rahul Bhati
 
Obesity dr njeru
Obesity dr njeruObesity dr njeru
Obesity dr njeru
Ahmedaedy
 
Management of Morbid Obesity
Management of Morbid ObesityManagement of Morbid Obesity
Management of Morbid ObesitySaurabh Kalia
 
Secrets of weight loss .pptx
Secrets of weight loss .pptxSecrets of weight loss .pptx
Secrets of weight loss .pptx
drgunasingh
 
obesity.pptx
obesity.pptxobesity.pptx
obesity.pptx
UtsavShinghal2
 
Endocrinology lectures ( obesity)
Endocrinology lectures ( obesity)Endocrinology lectures ( obesity)
Endocrinology lectures ( obesity)
Ahmed Elshebiny
 
Exercise prescription in obesity.pptx
Exercise prescription in obesity.pptxExercise prescription in obesity.pptx
Exercise prescription in obesity.pptx
DenishaBeladiya
 
Obesity in Adolescent- Right Time to Intervene
Obesity in Adolescent- Right Time to InterveneObesity in Adolescent- Right Time to Intervene
Obesity in Adolescent- Right Time to Intervene
Sujoy Dasgupta
 
Ch 7 and 8
Ch 7 and 8Ch 7 and 8
Ch 7 and 8
Matt Sanders
 
Diabetes in pregnancy 2
Diabetes in pregnancy 2Diabetes in pregnancy 2
Diabetes in pregnancy 2
obgymgmcri
 
obesity - a systematic approach
obesity - a systematic approachobesity - a systematic approach
obesity - a systematic approach
Chetan Ganteppanavar
 
OBESITY.pptx
OBESITY.pptxOBESITY.pptx
OBESITY.pptx
riyazameer
 
Obesity....
 Obesity.... Obesity....
Obesity....
Dr Madhuri Rudraraju
 
Approach to weight loss.pptx
Approach to weight loss.pptxApproach to weight loss.pptx
Approach to weight loss.pptx
Gadeppa H
 
diabetes mellitus in children
diabetes mellitus in childrendiabetes mellitus in children
diabetes mellitus in children
Azad Haleem
 
Obesity & its management
Obesity  & its management Obesity  & its management
Obesity & its management
Dr. Rupendra Bharti
 
Obesity and Weight Management: Role of Pharmacy Professionals
Obesity and Weight Management: Role of Pharmacy ProfessionalsObesity and Weight Management: Role of Pharmacy Professionals
Obesity and Weight Management: Role of Pharmacy Professionals
Tatenda Chikwetu
 
Diabetes.pptx
Diabetes.pptxDiabetes.pptx
Diabetes.pptx
chitragupta55
 
Seminar on treatment of obesity
Seminar on treatment of obesitySeminar on treatment of obesity
Seminar on treatment of obesity
Sarbabhaum Tripathy
 
Obesity or over weight and its management
Obesity or over weight  and its managementObesity or over weight  and its management
Obesity or over weight and its management
Dr . Nishita Patel
 

Similar to Antiobesity drugs (20)

Obesity
ObesityObesity
Obesity
 
Obesity dr njeru
Obesity dr njeruObesity dr njeru
Obesity dr njeru
 
Management of Morbid Obesity
Management of Morbid ObesityManagement of Morbid Obesity
Management of Morbid Obesity
 
Secrets of weight loss .pptx
Secrets of weight loss .pptxSecrets of weight loss .pptx
Secrets of weight loss .pptx
 
obesity.pptx
obesity.pptxobesity.pptx
obesity.pptx
 
Endocrinology lectures ( obesity)
Endocrinology lectures ( obesity)Endocrinology lectures ( obesity)
Endocrinology lectures ( obesity)
 
Exercise prescription in obesity.pptx
Exercise prescription in obesity.pptxExercise prescription in obesity.pptx
Exercise prescription in obesity.pptx
 
Obesity in Adolescent- Right Time to Intervene
Obesity in Adolescent- Right Time to InterveneObesity in Adolescent- Right Time to Intervene
Obesity in Adolescent- Right Time to Intervene
 
Ch 7 and 8
Ch 7 and 8Ch 7 and 8
Ch 7 and 8
 
Diabetes in pregnancy 2
Diabetes in pregnancy 2Diabetes in pregnancy 2
Diabetes in pregnancy 2
 
obesity - a systematic approach
obesity - a systematic approachobesity - a systematic approach
obesity - a systematic approach
 
OBESITY.pptx
OBESITY.pptxOBESITY.pptx
OBESITY.pptx
 
Obesity....
 Obesity.... Obesity....
Obesity....
 
Approach to weight loss.pptx
Approach to weight loss.pptxApproach to weight loss.pptx
Approach to weight loss.pptx
 
diabetes mellitus in children
diabetes mellitus in childrendiabetes mellitus in children
diabetes mellitus in children
 
Obesity & its management
Obesity  & its management Obesity  & its management
Obesity & its management
 
Obesity and Weight Management: Role of Pharmacy Professionals
Obesity and Weight Management: Role of Pharmacy ProfessionalsObesity and Weight Management: Role of Pharmacy Professionals
Obesity and Weight Management: Role of Pharmacy Professionals
 
Diabetes.pptx
Diabetes.pptxDiabetes.pptx
Diabetes.pptx
 
Seminar on treatment of obesity
Seminar on treatment of obesitySeminar on treatment of obesity
Seminar on treatment of obesity
 
Obesity or over weight and its management
Obesity or over weight  and its managementObesity or over weight  and its management
Obesity or over weight and its management
 

More from Dr. Pooja

Vaccines 1
Vaccines  1Vaccines  1
Vaccines 1
Dr. Pooja
 
Superinfection
SuperinfectionSuperinfection
Superinfection
Dr. Pooja
 
Screening of antitussives and expectorants
Screening of antitussives and expectorantsScreening of antitussives and expectorants
Screening of antitussives and expectorants
Dr. Pooja
 
Screening hypnotic activity
Screening hypnotic activityScreening hypnotic activity
Screening hypnotic activity
Dr. Pooja
 
Pharmacokinetics ii
Pharmacokinetics  iiPharmacokinetics  ii
Pharmacokinetics ii
Dr. Pooja
 
NMDA receptors and drugs acting on them
NMDA receptors and drugs acting on themNMDA receptors and drugs acting on them
NMDA receptors and drugs acting on them
Dr. Pooja
 
Myeloid growth factors
Myeloid growth factorsMyeloid growth factors
Myeloid growth factors
Dr. Pooja
 
Management of adverse effects of cancer chemotherapy 2
Management of adverse effects of cancer chemotherapy  2Management of adverse effects of cancer chemotherapy  2
Management of adverse effects of cancer chemotherapy 2
Dr. Pooja
 
Management of adverse effects of cancer chemotherapy 1
Management of adverse effects of cancer chemotherapy  1Management of adverse effects of cancer chemotherapy  1
Management of adverse effects of cancer chemotherapy 1
Dr. Pooja
 
Drugs modulating cholinesterase enzyme
Drugs modulating cholinesterase enzymeDrugs modulating cholinesterase enzyme
Drugs modulating cholinesterase enzyme
Dr. Pooja
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
Dr. Pooja
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
Dr. Pooja
 
Anti arrhythmic drugs
Anti arrhythmic drugsAnti arrhythmic drugs
Anti arrhythmic drugs
Dr. Pooja
 

More from Dr. Pooja (13)

Vaccines 1
Vaccines  1Vaccines  1
Vaccines 1
 
Superinfection
SuperinfectionSuperinfection
Superinfection
 
Screening of antitussives and expectorants
Screening of antitussives and expectorantsScreening of antitussives and expectorants
Screening of antitussives and expectorants
 
Screening hypnotic activity
Screening hypnotic activityScreening hypnotic activity
Screening hypnotic activity
 
Pharmacokinetics ii
Pharmacokinetics  iiPharmacokinetics  ii
Pharmacokinetics ii
 
NMDA receptors and drugs acting on them
NMDA receptors and drugs acting on themNMDA receptors and drugs acting on them
NMDA receptors and drugs acting on them
 
Myeloid growth factors
Myeloid growth factorsMyeloid growth factors
Myeloid growth factors
 
Management of adverse effects of cancer chemotherapy 2
Management of adverse effects of cancer chemotherapy  2Management of adverse effects of cancer chemotherapy  2
Management of adverse effects of cancer chemotherapy 2
 
Management of adverse effects of cancer chemotherapy 1
Management of adverse effects of cancer chemotherapy  1Management of adverse effects of cancer chemotherapy  1
Management of adverse effects of cancer chemotherapy 1
 
Drugs modulating cholinesterase enzyme
Drugs modulating cholinesterase enzymeDrugs modulating cholinesterase enzyme
Drugs modulating cholinesterase enzyme
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
Anti arrhythmic drugs
Anti arrhythmic drugsAnti arrhythmic drugs
Anti arrhythmic drugs
 

Recently uploaded

Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 

Antiobesity drugs

  • 1.
  • 3.
  • 4. OBESITY • Defined as an excess of body fat. • Surrogate marker for body fat content Body Mass Index. • BMI= Weight (in kg) Height (in m2) • BMI not a direct estimate of adiposity; large muscle mass.
  • 5. OBESITY • Can also be defined as, • 25% or greater total body fat- men • 35% or greater- women • Estimation of % of total body fat: • Measurement of skin fold thickness • Bioelectrical impedance • Underwater weighing
  • 6. BODY MASS INDEX BODY MASS INDEX VALUES(kg/m2) NORMAL 18.5- 24.9 OVERWEIGHT 25-29.9 CLASS I OBESITY 30-34.9 CLASS II OBESITY 35-39.9 CLASS III OBESITY (EXTREME) > 40 According to National Institute of Health:
  • 7.
  • 8. EPIDEMIOLOGY • Obesity “Killer lifestyle disease” • According to WHO, • 1.2 billion people classified overweight worldwide • 3% of Indian population- obese • Lancet India is just behind US and China among top 10 countries with highest number of obese.
  • 9. OBESITY • Obesity results from greater energy intake than energy expenditure. • 9.3 Cal 1gm fat is stored. • Fat adipocytes SC tissue; IP cavity; liver & other tissues.
  • 10.
  • 11. OBESITY • Infancy; childhood hyperplastic obesity number of adipocytes • Adults Hypertrophic obesity size of adipocytes • Extremely obese size and number of adipocytes contains double amount of lipids as a lean person
  • 14.
  • 15.
  • 16. OBESITY AND GENETICS • 20-25% • How genes contribute to obesity??? • One/ more abnormality of pathway regulating feeding center • Abnormality of energy expenditure and fat storage
  • 18. • Neural centers regulating appetite, feeding, behavior and energy status: Hypothalamus; the amygdala; nucleus tractus solitarius (NTS). • Lateral nuclei hypothalamus feeding center • Ventromedial nuclei satiety center
  • 19. • Arcuate nucleus floor of 3rd ventricle in hypothalamus key site. • These centers possess high density receptors for neurotransmitters and hormones.
  • 20.
  • 21.
  • 22.
  • 24.
  • 25.
  • 27.
  • 29. • Orlistat- pancreatic lipase inhibitor • Sibutramine- serotonin-norepinephrine reuptake inhibitor • Rimonobant- cannabinoid type-1 receptor antagonist
  • 30. Newer drugs approved by FDA • Lorcaserin- June 2012 • Phentermine & Topiramate ER- July 2012 • Naltrexone & Bupropion- Sept 2014 • Liraglutide- Dec 2014
  • 31. ORLISTAT • Reversible inhibitor of lipase- inhibits absorption of dietary fats • Empirical formula- C29H53NO5 • Molecular weight- 495.7 • FDA approved- April 1999
  • 32. ORLISTAT- MECHANISM OF ACTION • Exerts therapeutic activity- lumen of stomach and small intestine • Covalent bond active serine residue site- gastric; pancreatic lipase • Inactivated enzyme inhibits hydrolysis of dietary fat (TG) to absorbable free fatty acids and monoglycerides.
  • 33. • Undigested TG unabsorbed caloric deficit positive effect on weight control. • Therapeutic dose- 120 mg TID- fat absorption inhibited by 30%
  • 34. ORLISTAT- ADR • Fatty/oily stool • Flatus with discharge • Fecal incontinence • Increased defecation • Abdominal cramps
  • 35. SIBUTRAMINE • Serotonin-norepinephrine reuptake inhibitor • Empiric formula- C17H29Cl2NO • Molecular weight- 334.33 • FDA approved- November 1997
  • 36. SIBUTRAMINE- MOA • Inhibits reuptake of serotonin; norepinephrine at hypothalamic sites • Increases levels of these substances- enhances satiety • Reduction in waist circumference • Decrease in plasma TG and VLDL • Increase in HDL • Dose- 5-15 mg/day
  • 37. SIBUTRAMINE- ADR • Dry mouth • Constipation • Insomnia • Increased BP; Heart rate
  • 38. RIMONABANT • Cannabinoid type-1 receptor antagonist • Developed for smoking cessation; facilitate weight loss • Initially used in pts with BMI> 30kg/m2 • Frequent adverse effects most notably severe depression risk of suicide this drug is no longer used clinically
  • 39. LORCASERIN • Serotonin 2C receptor agonist • Selectively activates serotonin 2C receptors in brain promotes satiety • Indicated as an adjunct to low calorie diet and increased physical activity • BMI> 27 kg/m2 associated with weight-related comorbid condition or BMI >30kg/m2
  • 40. LORCASERIN • Dose- 10 mg twice daily • ADR- • Headache, dizziness, fatigue • Nausea, dry mouth • Constipation • Backache • Cough • Hypoglycemia
  • 41. QSYMIA • Combination of Phentermine & Topiramate ER. • Phentermine mediates release of catecholamine's in hypothalamus reduced appetite; decreased food consumption • Topiramate precise mechanism unknown • Dose- start 3.75mg/23mg daily for 14 days; increase to 7.5mg/46mg once daily. • After 12 weeks, <3% weight loss discontinue
  • 42. QSYMIA- ADR • Paresthesia • Dizziness • Insomnia • Constipation • Dry mouth
  • 43. CONTRAVE • Naltrexone & Bupropion • Schedule for treatment: • Week 1 1 tab- morning • Week 2 1 tab- morning & evening • Week 3 2 tab- morning; 1 tab- evening • Week 4 2 tab- morning & evening • After 12 weeks, <5% weight loss discontinue
  • 44. CONTRAVE- MOA • Effect on 2 separate areas of brain • Hypothalamus • Mesolimbic dopamine circuit • Exact neurochemical effects not known
  • 45. CONTRAVE- ADR • Nausea, vomiting • Headache, dizziness, insomnia • Dry mouth • Constipation • Has potential to cause suicidal thoughts & behaviors.
  • 46. LIRAGLUTIDE • Glucagon like peptide 1 receptor agonist. • A physiological regulator of appetite; calorie intake • GLP-1 receptor- present in several areas of brain regulating appetite. • Dose- 3mg subcutaneously
  • 47. LIRAGLUTIDE- ADR • Hypoglycemia • Nausea, vomiting • Constipation • Dyspepsia • Fatigue, Dizziness • Pain abdomen
  • 48. OTHER TRIALS • Beloranib- May 2015, Phase II trial
  • 49. BARIATRIC SURGERY • Most effective long-term treatment for obesity • Several approaches used- performed laproscopically • Goal- disrupting release of ghrelin and other peptides enhancing satiety
  • 50. • Complications: • Post-operative respiratory problems, wound infection • Staple leaks, stomal stenosis, • Marginal ulcers and venous thrombosis

Editor's Notes

  1. High BMI may also be due to large muscle mass.
  2. These methods are rarely used in clinical practice; Hence BMI is the only method to assess obesity. Abdominal circumference >102cm in men and >88 in women Waist hip ratio >1 in men and >0.85 in women obesity
  3. The Western Pacific Region Office of WHO recommends that, amongst Asians, BMI > 23.0 is overweight and > 25.0 is obese.
  4. Obesity important cause of preventable death worldwide A study published in the noted medical journal Lancet says India is just behind US and china in this global hazard list of top 10 countries with highest number of obese people.
  5. Metabolic syndrome is a disorder of energy utilization and storage, diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, and low high-density lipoprotein (HDL) levels
  6. Once a person is obese and attains a stable weight energy intake = energy expenditure. For weight loss, energy intake should be less than energy expenditure.
  7. Sensation of hunger- craving for food; rhythmic contractions of stomach; restlessness; Sensation of appetite- desire for food; helps to choose quality of food to be eaten. Both these feelings are influenced by hypothalamus. Satiety centre- gives sense of nutritional satisfaction- inhibits feeding centre; In case of complete satiety- even in presence of highly appetizing food, the person refuses it.
  8. Also, the paraventricular nucleus, dorsomedial nucleus and arcuate nucleus play an important role in feeding regulation. Hormones and neurotransmitters are released from GIT and adipose tissue in stimulation to food intake. These converge into the arcuate nucleus
  9. Arcuate nucleus 2 types of neurons to control appetite & energy expenditure 1) anorexigenic POMC & CART; 2) orexigenic NPY/AGRP POMC release MSH acts on melanocortin receptors in PVN (MCR 3 and 4) activation of MCR decreased food intake and increased energy expenditure. This is mediated by activation of neuronal pathways projecting from PVN to nucleus tractus solitaries Defective signaling of this pathway is associated with obesity. Mutations of MCR-4 is the main cause for obesity and accounts for 5-6% of early onset obesity in children. AGRP inhibits MSH natural antagonist of MCR 3 and 4 increases food intake When energy stores deplete activation of orexigenic neurons release of NPY stimulates appetite.
  10. 2 major clinical trial sustained weight loss of 9-10% over 2 years
  11. Increases the levels of these substances in the synaptic cleft and enhances satiety
  12. Phentermine- a sympathomimetic; topiramate- antiepileptic Indicated in adjunct to low calorie diet and increased physical activity. BMI > 27 and if associated with other comorbidity. BMI> 30
  13. Naltrexone- an opioid antagonist Bupropion- an inhibitor of neuronal reuptake of dopamine and norepinephrine Indications same as previous drugs
  14. Indications same as other drugs
  15. After 12 weeks study, sustained progressive dose dependent weight loss of up to 11 kg from baseline Reduced hunger; food intake. Reduced total, LDL, Tg and increased HDL levels
  16. Vertical banded gastroplasty- Also known as stomach stapling; A small stomach pouch 15-30 ML capacity is created using bands/staples. At the bottom of the pouch is a small hole through which contents flow into the remainder of stomach and GIT Roux-en-Y gastric bypass- Stomach is divided into 2 pouches and small intestine is rearranged to connect to both.